Sitaxsentan for the treatment of pulmonary arterial hypertension
| Autor: | Richard A.F. Dixon, Reda E. Girgis |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Liver toxicity business.industry Endothelin receptor antagonist Exercise capacity medicine.disease Highly selective Pulmonary hypertension Clinical trial Right heart failure Internal medicine medicine Cardiology Molecular Medicine Cardiology and Cardiovascular Medicine Endothelin receptor business |
| Zdroj: | Future Cardiology. 3:377-385 |
| ISSN: | 1744-8298 1479-6678 |
| Popis: | Pulmonary arterial hypertension (PAH) is a life-threatening, progressive condition that eventually leads to right heart failure. Endothelin receptor antagonists (ETRAs) have been shown to be a safe and efficacious treatment for PAH. Sitaxsentan is a highly selective oral ETRA that, in clinical trials, has demonstrated significant improvements in exercise capacity, functional class and pulmonary hemodynamics in PAH. Sitaxsentan has been shown to be a well tolerated and effective agent with a durable response for the treatment of PAH, and is associated with a low incidence of liver toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|